BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3087341)

  • 1. [Modern methods for the manufacture of therapeutic coagulation factors].
    Fuhge P; Gratz P; Geiger H
    Behring Inst Mitt; 1986 Feb; (79):165-76. PubMed ID: 3087341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory and preclinical evaluation of the virus safety of coagulation factor concentrates.
    Horowitz B; Prince AM
    Dev Biol Stand; 1987; 67():291-302. PubMed ID: 3609483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches to plasma fractionation for improved recovery and the development of potentially useful clinical factors.
    Johnson AJ; Mathews RW; Fulton AJ
    Clin Haematol; 1984 Feb; 13(1):3-15. PubMed ID: 6426834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New trends in plasma fractionation.
    Steinbuch M
    Haematologia (Budap); 1983; 16(1-4):39-51. PubMed ID: 6207083
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of blood products and factor concentrates for coagulation therapy.
    Fritsma MG
    Clin Lab Sci; 2003; 16(2):115-9. PubMed ID: 12757192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality control in the development of coagulation factor concentrates.
    Snape TJ
    Dev Biol Stand; 1987; 67():141-7. PubMed ID: 3609474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preparation of prothrombin complex concentrates with reduced thrombogenicity].
    Dornheim G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(6):856-62. PubMed ID: 6187638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate.
    Hilfenhaus J; Nowak T
    Vox Sang; 1994; 67 Suppl 1():62-6. PubMed ID: 8091740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemostasis: a practical review of conservative and operative care.
    Shopnick RI; Brettler DB
    Clin Orthop Relat Res; 1996 Jul; (328):34-8. PubMed ID: 8653974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunopurified clotting factor concentrates.
    Mariani G; Di Nucci GD; Arcieri P
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S61-5. PubMed ID: 8177718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromatographic methods of fractionation.
    Friesen AD
    Dev Biol Stand; 1987; 67():3-13. PubMed ID: 3609484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clotting factor concentrates].
    Barthels M; Oldenburg J
    Hamostaseologie; 2008 Dec; 28(5):387-99. PubMed ID: 19132169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral inactivation vs biological activity.
    Barrowcliffe TW
    Dev Biol Stand; 1993; 81():125-35. PubMed ID: 8174795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photochemical inactivation of viruses and bacteriophage in plasma and plasma fractions.
    Morel P; Lin L; Wiesehahn G; Corash L
    Blood Cells; 1992; 18(1):27-41; Discussion 41-2. PubMed ID: 1617190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
    Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
    Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Substitution therapy with prothrombin complex concentrates in acquired coagulation disorders].
    Fischer M
    Wien Klin Wochenschr; 1983 Feb; 95(3):82-5. PubMed ID: 6858171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
    Roberts PL; Dunkerley C; McAuley A; Winkelman L
    Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The improved factor concentrate.
    Lillicrap D
    Hamostaseologie; 2009 Jan; 29(1):71-3. PubMed ID: 19151851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Production and characterization of a new prothrombin complex concentrate].
    Dornheim G; Wegner H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(4):614-28. PubMed ID: 2414191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.